Skip to content
  • menu secondaire

    • Investors
    • Careers
    • Terms of Use
    • privacy policy
    • Cookie policy
    • Contacts
    • Profile
      • About Transgene
      • Management Team
      • Board of Directors
      • Corporate governance
      • Ethics & compliance
      • Collaborations
      • Partners
    • Technology
      • Viral-based Immunotherapies
        • Therapeutic Vaccines
        • Oncolytic Viruses
      • myvac Platform
      • Invir.IO Platform
      • Publications and Presentations
    • Portfolio
      • Pipeline
      • TG4050
      • TG4001
      • TG6002
      • TG6050
      • BT-001
      • Clinical trials FAQ
    • Press Releases
    • French

    Category: 2019

    Transgene Announces Financial Calendar for 2020

    20191218 Financial calendar 2020 EN

    Published 18 December 2019
    Categorized as 2019, Press release

    Transgene Reports on the Combination Trial of TG4010, Chemotherapy and Nivolumab in Non-Small Cell Lung Cancer

    20191212 PR TG4010_EN_results

    Published 12 December 2019
    Categorized as 2019, Press release, TG4010

    Transgene and BioInvent announce compelling preclinical data for BT-001 in solid tumors

    20191211 PR preclinical BT001 EN

    Published 11 December 2019
    Categorized as 2019, BT-001, Invir.IO, Press release

    Transgene Announces Investor Meetings for January 2020

    20191209 PR Investors Meeting agenda 2020

    Published 9 December 2019
    Categorized as 2019, Press release

    Transgene Provides Q3 2019 Business Update, with Focus on Recently Announced Efficacy Results of TG4001

    20191114 Résultats T3-2019 EN

    Published 14 November 2019
    Categorized as 2019, Press release

    Meta analysis of two phase 1b randomized, double blind, placebo controlled clinical trials of the HBV therapeutic vaccines TG1050 and T101 developed in Europe/Canada or China

    Poster 0710-AASLD 2019-TG1050-T101_Metaanalyse Fabien Zoulim et al. AASLD 2019 Download the poster here Poster Presentation

    Published 8 November 2019
    Categorized as 2019, Publication, TG1050

    Transgene Will Participate in the Jefferies 2019 London Healthcare Conference

    20191022 – Transgene PR Jefferies EN

    Published 22 October 2019
    Categorized as 2019, Press release

    Transgene Reports First Promising Efficacy Results with TG4001 in Combination with Avelumab in HPV-Positive Cancer at ESMO 2019

    20190930 PR TG4001 ESMO EN

    Published 30 September 2019
    Categorized as 2019, Press release, TG4001, TG4001

    Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic HPV16 positive cancers

    Christophe Le Tourneau et al. ESMO 2019 Download the poster here Poster Presentation

    Published 30 September 2019
    Categorized as 2019, Publication, TG4001, TG4001

    Transgene Confirms the Timeline of its Clinical News Flow and Presents 2019 Half-Year Results

    20190918-Transgene-H1-2019-RESULTS-EN

    Published 18 September 2019
    Categorized as 2019, Press release

    Posts navigation

    Page 1 … Page 4 Older posts
    • Investors
    • Careers
    • Terms of Use
    • privacy policy
    • Cookie policy
    • Contacts

    Transgene sa
    400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166
    67405 Illkirch Graffenstaden Cedex - France |
    Tel. : + 33 (0) 3 88 27 91 00

     

    © 2021 Transgene - All rights reserved
    Credits

    This Website uses cookies to provide you with the most relevant experience. By clicking on the "Accept All" button, you agree to the deposit of all cookies on your terminal. You can change your preferences or withdraw your consent at any time by clicking on the "Settings" button.
    More informationSettings Decline all ACCEPT ALL
    Cookies

    Privacy Overview

    This website uses cookies to improve your experience while you browse the website. Of these, cookies categorized as necessary are stored on your browser as they are essential for the functioning of basic functionalities of the website. We also use third-party cookies which advise us to analyze and understand how you use this website. These cookies will only be stored in your browser with your consent. You also have the option of deactivating these cookies. But disabling some of these cookies may affect your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously. Analytical cookies used to understand how visitors interact with the website.
    Functional (video)
    Functional cookies help to perform certain functions such as sharing website content on social media platforms, collecting feedback and other third-party functionality.
    Third-party application cookies (twitter)
    Cookies déposés par des sociétés autres que Transgene. Ces cookies sont susceptibles de transmettre aux sociétés tiers des informations en lien avec les pages consultées. Ces sociétés doivent s’engager à garder ces données confidentielles dans le cadre de la loi informatique et libertés (6 janvier 1978).
    Save & Accept
    Powered by CookieYes Logo